Neera Clase - 03 Nov 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
05 Nov 2026, 16:40:21 UTC
Prior SEC filing
05 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Sieckert, Attorney-in-Fact
Filing notes and source

Key filing fact

Neera Clase filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 05 Nov 2026.

Key facts

  • This page summarizes Neera Clase's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 05 Nov 2026, 16:40.

Change

  • Previous filing in this sequence was filed on 05 Nov 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002162845 Primary reporting owner

Clase Neera

Relationship
Chief Commercial Officer
Address
C/O TARSUS PHARMACEUTICALS, INC., 17700 LAGUNA CANYON ROAD, FLOOR 4, IRVINE
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Signature date
05 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+10,587
Change %
Price
$0.000000*
Shares after
10,587
Date
03 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,587
Exercise price
$72.64
Footnotes
F1
TARS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+6,678
Change %
Price
$0.000000*
Shares after
6,678
Date
03 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,678
Exercise price
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

25% of the option shares shall vest on November 1, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

Footnote F3

The RSUs will vest in four equal annual installments on December 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .